{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T10:07:43Z","timestamp":1791799663205,"version":"4.3.4"},"reference-count":103,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"NSERC of Canada","award":["418505-2012"],"award-info":[{"award-number":["418505-2012"]}]},{"name":"Memorial University"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.bbapap.2017.05.009","type":"journal-article","created":{"date-parts":[[2017,5,18]],"date-time":"2017-05-18T13:52:00Z","timestamp":1495115520000},"page":"1664-1675","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"special_numbering":"PB","title":["Modeling covalent-modifier drugs"],"prefix":"10.1016","volume":"1865","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9127-8539","authenticated-orcid":false,"given":"Ernest","family":"Awoonor-Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0205-952X","authenticated-orcid":false,"given":"Christopher N.","family":"Rowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbapap.2017.05.009_bb0005","doi-asserted-by":"crossref","first-page":"9997","DOI":"10.1073\/pnas.96.18.9997","article-title":"The maximal affinity of ligands","volume":"96","author":"Kuntz","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0010","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1021\/acs.jmedchem.6b00788","article-title":"Covalent modifiers: a chemical perspective on the reactivity of ,-unsaturated carbonyls with thiols via hetero-Michael addition reactions","volume":"60","author":"Jackson","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0015","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1021\/jm8008597","article-title":"Covalent modifiers: an orthogonal approach to drug design","volume":"52","author":"Potashman","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0020","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd3410","article-title":"The resurgence of covalent drugs","volume":"10","author":"Singh","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0025","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1517\/17460441.2012.688744","article-title":"Drug discovery for a new generation of covalent drugs","volume":"7","author":"Kalgutkar","year":"2012","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0030","doi-asserted-by":"crossref","first-page":"7463","DOI":"10.1021\/jm400224q","article-title":"Keap calm, and carry on covalently","volume":"56","author":"Wilson","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0035","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.drudis.2015.05.005","article-title":"Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies","volume":"20","author":"Bauer","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bbapap.2017.05.009_bb0040","doi-asserted-by":"crossref","first-page":"13408","DOI":"10.1002\/anie.201601091","article-title":"Targeted covalent inhibitors for drug design","volume":"55","author":"Baillie","year":"2016","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0045","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1021\/cr010182v","article-title":"Irreversible inhibitors of serine, cysteine, and threonine proteases","volume":"102","author":"Powers","year":"2002","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0050","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/oxfordjournals.molbev.a026406","article-title":"Relationship between the occurrence of cysteine in proteins and the complexity of organisms","volume":"17","author":"Miseta","year":"2000","journal-title":"Mol. Biol. Evol."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0055","doi-asserted-by":"crossref","first-page":"7590","DOI":"10.1021\/jm5006918","article-title":"Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments","volume":"57","author":"J\u00f6st","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0060","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nature18002","article-title":"Proteome-wide covalent ligand discovery in native biological systems","volume":"534","author":"Backus","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bbapap.2017.05.009_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2016.12.029","article-title":"Ligand and target discovery by fragment-based screening in human cells","volume":"168","author":"Parker","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bbapap.2017.05.009_bb0070","doi-asserted-by":"crossref","first-page":"949","DOI":"10.4155\/fmc.10.21","article-title":"Strategies for discovering and derisking covalent, irreversible enzyme inhibitors","volume":"2","author":"Johnson","year":"2010","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0075","first-page":"1330","article-title":"Reversible Michael additions: covalent inhibitors and prodrugs","volume":"12","author":"Johansson","year":"2012","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0080","doi-asserted-by":"crossref","first-page":"6825","DOI":"10.1073\/pnas.0409005102","article-title":"Calculation of absolute protein-ligand binding free energy from computer simulations","volume":"102","author":"Woo","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0085","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nchembio.204","article-title":"A 21st century revisionist's view at a turning point in enzymology","volume":"5","author":"Nagel","year":"2009","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0090","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1098\/rstb.2006.1880","article-title":"Transition state theory can be used in studies of enzyme catalysis: lessons from simulations of tunnelling and dynamical effects in lipoxygenase and other systems","volume":"361","author":"Olsson","year":"2006","journal-title":"Philos. Trans. R. Soc., B"},{"key":"10.1016\/j.bbapap.2017.05.009_bb0095","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nrd2082","article-title":"Drug-target residence time and its implications for lead optimization","volume":"5","author":"Copeland","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0100","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nchembio.1817","article-title":"Prolonged and tunable residence time using reversible covalent kinase inhibitors","volume":"11","author":"Bradshaw","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0105","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nrd.2015.18","article-title":"The drug-target residence time model: a 10-year retrospective","volume":"15","author":"Copeland","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0110","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/jps.21494","article-title":"Calculation of molecular lipophilicity: state-of-the-art and comparison of logP methods on more than 96,000 compounds","volume":"98","author":"Mannhold","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0115","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.bbamem.2015.12.014","article-title":"Molecular simulation of nonfacilitated membrane permeation","volume":"1858","author":"Awoonor-Williams","year":"2016","journal-title":"Biochim. Biophys. Acta, Biomembr."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0120","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1021\/acs.jcim.6b00022","article-title":"Simulation-based approaches for determining membrane permeability of small compounds","volume":"56","author":"Lee","year":"2016","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0125","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jmr.1077","article-title":"Challenges and advances in computational docking: 2009 in review","volume":"24","author":"Yuriev","year":"2011","journal-title":"J. Mol. Recogn."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0130","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1208\/s12248-012-9322-0","article-title":"Structure-based virtual screening for drug discovery: a problem-centric review","volume":"14","author":"Cheng","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0135","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1124\/pr.112.007336","article-title":"Computational methods in drug discovery","volume":"66","author":"Sliwoski","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0140","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1529\/biophysj.106.084301","article-title":"Absolute binding free energy calculations using molecular dynamics simulations with restraining potentials","volume":"91","author":"Wang","year":"2006","journal-title":"Biophys J."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0145","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s10822-010-9363-3","article-title":"Prediction of protein-ligand binding affinity by free energy simulations: assumptions, pitfalls and expectations","volume":"24","author":"Michel","year":"2010","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0150","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.sbi.2011.01.011","article-title":"Alchemical free energy methods for drug discovery: progress and challenges","volume":"21","author":"Chodera","year":"2011","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0155","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1021\/ja512751q","article-title":"Accurate and reliable prediction of relative ligand\u00a0binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field","volume":"137","author":"Wang","year":"2015","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0160","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.3390\/molecules20021984","article-title":"Theory and applications of covalent docking in drug discovery: merits and pitfalls","volume":"20","author":"Kumalo","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.bbapap.2017.05.009_bb0165","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The Protein Data Bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0170","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nbt.1990","article-title":"Comprehensive analysis of kinase inhibitor selectivity","volume":"29","author":"Davis","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0175","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1021\/jm3003203","article-title":"Irreversible protein kinase inhibitors: balancing the benefits and risks","volume":"55","author":"Barf","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0180","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.chembiol.2012.12.006","article-title":"Developing irreversible inhibitors of the protein kinase cysteinome","volume":"20","author":"Liu","year":"2013","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0185","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science1108367","article-title":"Structural bioinformatics-based design of selective, irreversible kinase inhibitors","volume":"308","author":"Cohen","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.bbapap.2017.05.009_bb0190","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrc2559","article-title":"Targeting cancer with small molecule kinase inhibitors","volume":"9","author":"Zhang","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbapap.2017.05.009_bb0195","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1021\/jm101396q","article-title":"Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors","volume":"54","author":"Leproult","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0200","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.bbrc.2016.08.109","article-title":"Cysteinome: the first comprehensive database for proteins with targetable cysteine and their covalent inhibitors","volume":"478","author":"Wu","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0205","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.1021\/acs.jctc.6b00631","article-title":"Evaluation of methods for the calculation of the pKa of cysteine residues in Proteins","volume":"12","author":"Awoonor-Williams","year":"2016","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0210","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1021\/acs.jmedchem.5b02041","article-title":"Delineation of polypharmacology across the human structural kinome using a functional site interaction fingerprint Approach","volume":"59","author":"Zhao","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0215","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1021\/acs.jmedchem.6b01815","article-title":"Determining cysteines available for covalent inhibition across the human kinome","volume":"60","author":"Zhao","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0220","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s10822-004-5291-4","article-title":"Unsupervised guided docking of covalently bound ligands","volume":"18","author":"Fradera","year":"2004","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0225","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1021\/acs.accounts.6b00185","article-title":"Medicinal chemistry projects requiring imaginative structure-based drug design methods","volume":"49","author":"Moitessier","year":"2016","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0230","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/nchembio.1666","article-title":"Covalent docking of large libraries for the discovery of chemical probes","volume":"10","author":"London","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0235","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1021\/ci500118s","article-title":"Docking covalent inhibitors: a parameter free approach to pose prediction and scoring","volume":"54","author":"Zhu","year":"2014","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0240","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1021\/ci500175r","article-title":"Structure-based virtual screening approach for discovery of covalently bound ligands","volume":"54","author":"Toledo Warshaviak","year":"2014","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0245","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/pro.2733","article-title":"Covalent docking using autodock:\u00a0two-point attractor and flexible side chain methods","volume":"25","author":"Bianco","year":"2016","journal-title":"Protein Sci."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0250","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1021\/ci500681r","article-title":"DOCKTITE - A highly versatile step-by-step workflow for covalent docking and virtual screening in the molecular operating environment","volume":"55","author":"Scholz","year":"2015","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0255","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1021\/ci6002637","article-title":"Docking ligands into flexible and solvated macromolecules. 1. Development and Validation of FITTED 1.0","volume":"47","author":"Corbeil","year":"2007","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0260","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1021\/ci8004176","article-title":"Docking ligands into flexible and solvated macromolecules. 3. Impact of Input Ligand Conformation, Protein Flexibility, and Water Molecules on the Accuracy of Docking Programs","volume":"49","author":"Corbeil","year":"2009","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0265","doi-asserted-by":"crossref","first-page":"6672","DOI":"10.1021\/jm901013a","article-title":"Constrained peptidomimetics reveal detailed geometric requirements of covalent prolyl oligopeptidase inhibitors","volume":"52","author":"Lawandi","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0270","doi-asserted-by":"crossref","first-page":"6306","DOI":"10.1021\/jm3002839","article-title":"Virtual screening and computational optimization for the discovery of covalent prolyl oligopeptidase inhibitors with activity in human cells","volume":"55","author":"De Cesco","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0275","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.1021\/acs.jmedchem.5b01296","article-title":"3-Oxo-hexahydro-1H-isoindole-4-carboxylic acid as a drug chiral bicyclic scaffold: structure-based design and preparation of conformationally constrained covalent and noncovalent prolyl oligopeptidase inhibitors","volume":"59","author":"Mariaule","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0280","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10822-010-9324-x","article-title":"A computational workflow for the design of irreversible inhibitors of protein kinases","volume":"24","author":"Del Rio","year":"2010","journal-title":"J Comput. Aided Mol. Des."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0285","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/jcc.23136","article-title":"CovalentDock: automated covalent docking with parameterized covalent linkage energy estimation and molecular geometry constraints","volume":"34","author":"Ouyang","year":"2013","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0290","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkt406","article-title":"CovalentDock Cloud: a web server for automated covalent docking","volume":"41","author":"Ouyang","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0295","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/pro.2733","article-title":"Covalent docking using autodock: two-point attractor and flexible side chain methods","volume":"25","author":"Bianco","year":"2016","journal-title":"Protein Sci."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0300","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0022-2836(02)00470-9","article-title":"On the role of the crystal environment in determining protein side-chain conformations","volume":"320","author":"Jacobson","year":"2002","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0305","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/prot.10613","article-title":"A hierarchical approach to all-atom protein loop prediction","volume":"55","author":"Jacobson","year":"2004","journal-title":"Proteins: Struct., Funct., Bioinf."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0310","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1021\/acs.jcim.6b00334","article-title":"Discovery of covalent ligands via noncovalent docking by dissecting covalent docking based on a \u2018steric-clashes alleviating receptor (SCAR)\u201d strategy","volume":"56","author":"Ai","year":"2016","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0315","series-title":"Molecular Operating Environment (MOE) 2013.08 Chemical Computing Group Inc. 1010 Sherbrooke St. West Suite #910 Montreal Q, Canada H3A 2R7","year":"2017"},{"key":"10.1016\/j.bbapap.2017.05.009_bb0320","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bmcl.2016.11.036","article-title":"Evaluation of dipeptide nitriles as inhibitors of rhodesain, a major cysteine protease of Trypanosoma brucei","volume":"27","author":"Schirmeister","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0325","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1110\/ps.051840806","article-title":"pK values of the ionizable groups of proteins","volume":"15","author":"Thurlkill","year":"2006","journal-title":"Protein Sci."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0330","doi-asserted-by":"crossref","first-page":"9968","DOI":"10.1021\/bi9705974","article-title":"A classical enzyme active center motif lacks catalytic competence until modulated electrostatically","volume":"36","author":"Pinitglang","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/j.bbapap.2017.05.009_bb0335","doi-asserted-by":"crossref","first-page":"10219","DOI":"10.1021\/bi00496a010","article-title":"pKa's of ionizable groups in proteins: atomic detail from a continuum electrostatic model","volume":"29","author":"Bashford","year":"1990","journal-title":"Biochemistry"},{"key":"10.1016\/j.bbapap.2017.05.009_bb0340","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1021\/ja039788m","article-title":"Proton binding to proteins: pKa calculations with explicit and implicit solvent models","volume":"126","author":"Simonson","year":"2004","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0345","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1002\/prot.23189","article-title":"Progress in the prediction of pKa values in proteins","volume":"79","author":"Alexov","year":"2011","journal-title":"Proteins: Struct., Funct., Bioinf."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0350","doi-asserted-by":"crossref","DOI":"10.1063\/1.3021474","article-title":"Delocalization errors in density functionals and implications for main-group thermochemistry","volume":"129","author":"Johnson","year":"2008","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0355","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1126\/science.1158722","article-title":"Insights into current limitations of density functional theory","volume":"321","author":"Cohen","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.bbapap.2017.05.009_bb0360","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1021\/ar500171t","article-title":"Delocalization error and functional tuning in KohnSham calculations of molecular properties","volume":"47","author":"Autschbach","year":"2014","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0365","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-physchem-052516-044957","article-title":"The importance of being self-consistent","author":"Wasserman","year":"2017","journal-title":"Annu. Rev. Phys. Chem."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0370","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1021\/ct400773k","article-title":"Range-separated DFT functionals are necessary to model Thio-Michael additions","volume":"9","author":"Smith","year":"2013","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0375","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1021\/jo200761w","article-title":"Transition states and energetics of nucleophilic additions of thiols to substituted -unsaturated ketones: substituent effects involve enone stabilization, product branching, and solvation","volume":"76","author":"Krenske","year":"2011","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0380","doi-asserted-by":"crossref","first-page":"12624","DOI":"10.1021\/ja505194w","article-title":"Design of reversible, cysteine-targeted Michael acceptors guided by kinetic and computational analysis","volume":"136","author":"Krishnan","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0385","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s10822-015-9857-0","article-title":"Automated computational screening of the thiol reactivity of substituted alkenes","volume":"29","author":"Smith","year":"2015","journal-title":"J. Comput.-Aided Mol. Des."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0390","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.2088","article-title":"An explicit-solvent conformation search method using open software.","volume":"4","author":"Gaalswyk","year":"2016","journal-title":"PeerJ"},{"key":"10.1016\/j.bbapap.2017.05.009_bb0395","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nchembio.925","article-title":"Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles","volume":"8","author":"Serafimova","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0400","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1073\/pnas.1313733111","article-title":"Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance","volume":"111","author":"Schwartz","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbapap.2017.05.009_bb0405","doi-asserted-by":"crossref","first-page":"11726","DOI":"10.1021\/acs.joc.6b02188","article-title":"Kinetics and thermodynamics of reversible thiol additions to mono- and diactivated Michael acceptors: implications for the design of drugs that bind covalently to cysteines","volume":"81","author":"Krenske","year":"2016","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0410","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1021\/ct301082y","article-title":"Benchmark study for the cysteine-histidine proton transfer reaction in a protein environment: gas phase, COSMO, QM\/MM approaches","volume":"9","author":"Paasche","year":"2013","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0415","series-title":"Gaussian16 Revision A.03","author":"Frisch","year":"2016"},{"key":"10.1016\/j.bbapap.2017.05.009_bb0420","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1002\/jcc.23716","article-title":"The CHARMM-TURBOMOLE interface for efficient and accurate QM\/MM molecular dynamics, free energies, and excited state properties","volume":"35","author":"Riahi","year":"2014","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0425","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/jcc.20857","article-title":"The implementation of a fast and accurate QM\/MM potential method in Amber","volume":"29","author":"Walker","year":"2008","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0430","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/jcc.20289","article-title":"Scalable molecular dynamics with NAMD","volume":"26","author":"Phillips","year":"2005","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0435","first-page":"1","article-title":"QUASI: a general purpose implementation of the QM\/MM approach and its application to problems in catalysis","volume":"632","author":"Sherwood","year":"2003","journal-title":"Comp. Theor. Chem."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0440","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/wcms.1163","article-title":"ChemShell - a modular software package for QM\/MM simulations","volume":"4","author":"Metz","year":"2014","journal-title":"Wiley Interdiscip. Rev. Comput. Mol. Sci."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0445","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/cmdc.200800438","article-title":"Mechanistic insights into cyclooxygenase irreversible inactivation by aspirin","volume":"4","author":"Tosco","year":"2009","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bbapap.2017.05.009_bb0450","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jmgm.2012.12.013","article-title":"Mechanism of the irreversible inhibition of human cyclooxygenase-1 by aspirin as predicted by QM\/MM calculations","volume":"40","author":"Toth","year":"2013","journal-title":"J. Mol. Graphics Modell."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0455","doi-asserted-by":"crossref","first-page":"13633","DOI":"10.1021\/ja074222+","article-title":"Molecular dynamics simulations of the catalytic pathway of a cysteine protease: a combined QM\/MM study of human cathepsin K","volume":"129","author":"Ma","year":"2007","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0460","doi-asserted-by":"crossref","first-page":"8696","DOI":"10.1021\/ja711043x","article-title":"On the origin of the stabilization of the zwitterionic resting state of cysteine proteases: a theoretical study","volume":"130","author":"Mladenovic","year":"2008","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0465","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1021\/bi500060h","article-title":"Quantum mechanics\/molecular mechanics studies of the mechanism of falcipain-2 inhibition by the epoxysuccinate E64","volume":"53","author":"Arafet","year":"2014","journal-title":"Biochemistry"},{"key":"10.1016\/j.bbapap.2017.05.009_bb0470","doi-asserted-by":"crossref","first-page":"5282","DOI":"10.1021\/jp810549n","article-title":"Rational design of improved aziridine-based inhibitors of cysteine proteases","volume":"113","author":"Buback","year":"2009","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.bbapap.2017.05.009_bb0475","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/prot.22939","article-title":"The mechanism of papain inhibition by peptidyl aldehydes","volume":"79","author":"Shokhen","year":"2011","journal-title":"Proteins: Struct., Funct., Bioinf."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0480","doi-asserted-by":"crossref","first-page":"14973","DOI":"10.1021\/jp409604n","article-title":"Quantum mechanics-based scoring rationalizes the irreversible inactivation of parasitic Schistosoma mansoni cysteine peptidase by vinyl sulfone inhibitors","volume":"117","author":"Fanfrl\u00edk","year":"2013","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.bbapap.2017.05.009_bb0485","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1021\/acsmedchemlett.6b00276","article-title":"Dipeptidyl nitroalkenes as potent reversible inhibitors of cysteine proteases Rhodesain and Cruzain","volume":"7","author":"Latorre","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bbapap.2017.05.009_bb0490","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/cmdc.200600159","article-title":"The importance of the active site histidine for the activity of epoxide-or aziridine-based inhibitors of cysteine proteases","volume":"2","author":"Mladenovic","year":"2007","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bbapap.2017.05.009_bb0495","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1021\/jp711287c","article-title":"Atomistic insights into the inhibition of cysteine proteases: first QM\/MM calculations clarifying the regiospecificity and the inhibition potency of epoxide-and aziridine-based inhibitors","volume":"112","author":"Mladenovic","year":"2008","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.bbapap.2017.05.009_bb0500","doi-asserted-by":"crossref","first-page":"11798","DOI":"10.1021\/jp803895f","article-title":"Atomistic insights into the inhibition of cysteine proteases: first QM\/MM calculations clarifying the stereoselectivity of epoxide-based inhibitors","volume":"112","author":"Mladenovic","year":"2008","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.bbapap.2017.05.009_bb0505","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/cmdc.200600081","article-title":"Rational design of aziridine-containing cysteine protease inhibitors with improved potency: studies on inhibition mechanism","volume":"1","author":"Vicik","year":"2006","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bbapap.2017.05.009_bb0510","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/cmdc.200600106","article-title":"Aziridide-based inhibitors of cathepsinL: synthesis, inhibition activity, and docking studies","volume":"1","author":"Vicik","year":"2006","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bbapap.2017.05.009_bb0515","doi-asserted-by":"crossref","first-page":"8332","DOI":"10.1021\/jacs.6b03052","article-title":"Quantum chemical-based protocol for the rational design of covalent inhibitors","volume":"138","author":"Schirmeister","year":"2016","journal-title":"J. Am. Chem. Soc."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570963917301097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570963917301097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T16:33:43Z","timestamp":1569342823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570963917301097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":103,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S1570963917301097"],"URL":"https:\/\/doi.org\/10.1016\/j.bbapap.2017.05.009","relation":{},"ISSN":["1570-9639"],"issn-type":[{"value":"1570-9639","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modeling covalent-modifier drugs","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbapap.2017.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}